ArticleCurrent oncology (Toronto, Ont.)2022
Low Platelet Count Predicts Reduced Survival in Potentially Resectable Hepatocellular Carcinoma.
Article in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- LaparoscopicTranslational gastroenterology and hepatology · 2026Article
- Construction of a Preoperative Prediction Model for TACE Resistance in Primary Hepatocellular Carcinoma Based on Machine Learning Algorithms.Journal of hepatocellular carcinoma · 2026Article
- A prognostic model based on gamma-glutamyl transpeptidase-derived neutrophil-platelet for predicting intrahepatic recurrence in hepatocellular carcinoma.Discover oncology · 2025Review
- Impact of thrombocytopenia and coagulopathy on partial hepatectomy and Hassab's operation in patients with cirrhosis: a multicenter retrospective cohort study.Annals of medicine · 2025Article
- The causal relationship between platelet indices and liver cancer: a bidirectional two-sample Mendelian randomization study.Discover oncology · 2025Article
- Review
- Predictive factors and prognostic models for Hepatic arterial infusion chemotherapy in Hepatocellular carcinoma: a comprehensive review.World journal of surgical oncology · 2025Review
- Development and clinical validation of a novel platelet count-based nomogram for predicting microvascular invasion in HCC.Scientific reports · 2025Article
- Prognostic Significance of Elevated Platelet Count (>200 x 10^9 per L) in BCLC Stages B and C of Hepatocellular Carcinoma: A Retrospective Multicenter Analysis.Journal of hepatocellular carcinoma · 2025Article
- Application of propensity score matching in prognostic analysis of portal hypertension in hepatocellular carcinoma patients.Frontiers in oncology · 2025Article
- Article
- The Many Faces of Immune Thrombocytopenia: Mechanisms, Therapies, and Clinical Challenges in Oncological Patients.Journal of clinical medicine · 2024Review
- Diagnostic performance of non-invasive liver fibrosis scores in patients with early-intermediate hepatocellular carcinoma.Journal of cancer research and clinical oncology · 2024Article
- Impact of Thrombocytopenia on Survival in Patients with Hepatocellular Carcinoma: Updated Meta-Analysis and Systematic Review.Cancers · 2024Review
- Prospects of liquid biopsy in the prognosis and clinical management of gastrointestinal cancers.Frontiers in molecular biosciences · 2024Review
- Diagnostic value of serum inflammatory markers in predicting early refractoriness of transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer Stage 0, A, and B hepatocellular carcinoma.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024Article
- Clinical manifestation, staging and prognosis of hepatocellular carcinoma in Gambian patients.BMC gastroenterology · 2023Article
- Genetic Analysis of Platelet-Related Genes in Hepatocellular Carcinoma Reveals a Novel Prognostic Signature and Determines PRKCD as the Potential Molecular Bridge.Biological procedures online · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
The prognostic role of platelet count in hepatocellular carcinoma (HCC) remains unclear, and in fact both thrombocytopenia and thrombocytosis are reported as predictors of unfavourable outcomes. This study aimed to clarify the prognostic value of preoperative platelet count in potentially resectable HCC. We retrospectively reviewed 128 patients who underwent hepatic resection for HCC at a tertiary academic centre (2007−2019). Patient data were modelled by regression analysis, and platelet count was treated as a continuous variable. 89 patients had BCLC 0/A tumours and 39 had BCLC B tumours. Platelet count was higher in patients with larger tumours and lower in patients with higher MELD scores, advanced fibrosis, and portal hypertension (p < 0.001 for all listed variables). After adjusting for BCLC stage and tumour diameter, low platelet count associated with reduced overall survival (hazard ratio 1.25 per 50/nL decrease in platelet count, 95% confidence interval (CI) 1.02−1.53, p = 0.034) and increased perioperative mortality (odds ratio 1.96 per 50/nL decrease in platelet count, 95% CI 1.19−3.53, p = 0.014). Overall, low platelet count correlates with increased liver disease severity, inferior survival, and excess perioperative mortality in resectable HCC. These insights might be applied in clinical practice to better select patients for resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.